

SECTOR UPDATE

Plantation – Singapore

What Goes Up Must Come Down

CPO prices have corrected 28% since Indonesia announced the lifting of the export ban. After this CPO price correction, we are seeing some positives emerge to prevent further price deterioration: a) it is commercially viable to increase biodiesel mandate or non-mandatory biodiesel blending, and b) demand recovery is in sight in India and China. But Indonesia's palm oil industry has clearly not benefitted from the high CPO prices over the last six months. Maintain MARKET WEIGHT.

WHAT'S NEW

- **Sharp CPO price correction came earlier than expected.** CPO prices corrected 28% since Indonesia uplifted the exports ban. CPO 3-month futures hit a low of RM4,493/tonne yesterday. The sharp correction came earlier than expected. We attribute the sell-down on CPO to: a) the expectation of more exports from Indonesia (which we are yet to see happen) to reduce the high stocks domestically, b) rising recession risk also triggers the fear that demand may weaken further, and c) crops production output in Ukraine and Russia are better than expected. In addition, the sell-down on CPO futures also may be due to the concern of liquidity withdrawal as the Fed tightened the monetary policy.
- **Indonesia's CPO prices corrected more sharply.** Indonesia's domestic CPO net selling prices are estimated to have weakened by 35% since the exports ban was lifted on 23 May 22. This correction is slightly sharper than Malaysia's spot and future prices which declined by 21% and 28% for the same period of time. We attribute this to the oversupply of palm oil domestically in Indonesia as the export is not fast enough to ease the high inventory pressure. Lower ASP and higher taxes have depressed the profit margin for Indonesian-based plantation companies especially the upstream players.
- **Wilmar's food product margins should recover in 2H22 with the correction in feedstock prices.** Wilmar's weak 1Q22 performance was partly affected by the margins compression for its food products due to high feedstock prices despite selling price adjustments. The recent 20-30% agri-commodity price correction should be a big relief to this division and should show good improvement in 2H22. On top of that, China's soybean crushing and soymeal sales have improved in tandem with the recovery in pig farming margin. The recovery in these two segments will be partly offset by the weaker earnings contributions from its upstream. Although the upstream earnings may not be as good as 1H22, it is still much better as compared with 2019 and 2020.

ACTION

- **Maintain MARKET WEIGHT.** CPO prices have weakened as expected and this has a larger negative impact to Indonesian-based plantation companies due to the significantly higher taxes imposed vs its Malaysian peers. In addition, the frequent changes in Indonesia's palm oil policies have significantly affected sales as well. This may have caused low investor interest given the uncertainties in the sector as well as companies' potentially disappointing earnings.
- **Adjusted our valuation.** We have rolled over our valuation to 2023 to better reflect the CPO price downtrend; we expect a lower average CPO price of RM4,000/tonne for 2023 vs RM5,200/tonne for 2022. With this, we have downgraded Bumitama Agri to HOLD with a lower target price of S\$0.65, while maintaining HOLD for First Resources at a lower target price at S\$1.70. We pegged both of the valuation at -2SD from its five-year mean. For Wilmar, we maintain BUY with a target price of S\$5.50 after rolling over our valuation to 2023 and factoring in a lower PE (from 12x to 10x) for its non-China operation while maintaining 26x valuation for the China operation.

PEER COMPARISON

Company	Ticker	Rec	Price @ 22 Jun 22	Target Price	Market Cap (US\$m)	PE			ROE	P/B	2022F Div	Div Yield
			(\$)	(\$)		2021 (x)	2022F (x)	2023F (x)	(%)	(x)	(cent)	(%)
Singapore												
Bumitama Agri	BAL SP	HOLD	0.67	0.65	836	10.2	7.5	5.6	17.8	1.7	3.7	5.5
First Resources	FR SP	HOLD	1.84	1.70	2,089	19.2	13.3	9.8	14.3	1.7	9.3	5.1
Wilmar International	WIL SP	BUY	4.02	5.50	18,152	11.6	9.4	10.0	9.7	0.9	16.1	4.0

Source: UOB Kay Hian

MARKET WEIGHT

(Maintained)

STOCK PICKS

Company	Rec	Share Price	Target Price
Wilmar International	BUY	4.02	5.50

Source: UOB Kay Hian

CPO PRICE ASSUMPTIONS (RM/TONNE)

	CPO Price (RM/tonne)
2020	2,686
2021	4,408
Our forecast:	
2022F	5,200
2023F	4,000
CPO Price:	
MPOB @ 21 June 22	5,233
BMD 3 rd Month Contract	4,563

Source: UOB Kay Hian

INDONESIA'S DOMESTIC CPO NET PRICE DIPPED BELOW DPO PRICE



Source: University Bengkulu

ANALYST(S)

Leow Huey Chuen
+603 2147 1990
hueychuen@uobkayhian.com

Jacquelyn Yow
+603 2147 1995
jacquelyn@uobkayhian.com

ESSENTIALS

• **Supportive factors are emerging.** We reckon the current price range is more reflective of fundamental factors, which is a reflection of the easing of supply tightness. CPO prices should be stabilising as current prices induce demand from the biodiesel segment, China and India.

- a) **Potentially more demand from biofuel segment.** Palm oil-gasoil (POGO) prices spread is turning negative, which means it is commercially viable to start non-mandated biodiesel blending. This is also encouraging amid the fuel shortage due to Black Sea Tensions. Just a week ago, Argentina has raised the biodiesel blending mandate on the backdrop of supply scarcity together with high diesel prices.
- b) **Demand recovery is seen in China** after the palm olein price premium to soybean oil narrowed significantly. The price premium has dropped from around Rmb4,000/tonne in late-April to around Rmb1,900/tonne currently. After the sharp price decline, demand for palm olein in China has been improving over the past weeks. China's palm oil inventory is at its historical low of 203,300 tonnes as at 17 Jun 22 vs the usual level of 400,000-600,000 tonnes. If the demand recovery sustains, China may need to increase the import of palm oil to meet the demand.
- c) **India may increase palm oil imports as margins turn positive.** The positive import margins should encourage higher palm oil imports by India. This price correction comes at a time when India usually increases import of vegoil to meet the high festive demand. Similar to the situation in China, palm oil inventory in India was also at a low level of 240,865 as at end-Apr 22 vs its usual 600,000-700,000 tonnes of inventory. Negative import margin has stopped India from importing palm oil.

ASSUMPTION CHANGES

- **CPO ASP assumptions.** We maintain our CPO price assumptions at RM5,200/tonne and RM4,000/tonne for 2022-23 respectively.

SECTOR CATALYSTS

- Higher-than-expected US green diesel demand.
- Stronger-than-expected commodity cycle.


REVISED RECOMMENDATION AND TARGET PRICES

	----- Recommendation -----		----- Target Price -----	
	Revise	Previous	Revise	Previous
Bumitama Agri	HOLD	BUY	0.65	0.96
First Resources	HOLD	HOLD	1.70	2.30
Wilmar International	BUY	BUY	5.50	5.50

Source: UOB Kay Hian


HIGH PALM OIL INVENTORIES AT PRODUCING COUNTRIES WHILE RECORD LOW AT TWO MAJOR CONSUMING COUNTRIES

PALM OIL INVENTORIES IN INDONESIA AND MALAYSIA



Source: MPOB, GAPKI

PALM OIL INVENTORY IN INDIA AND CHINA




Source: SEA, EPANSUN

CORRECTION IN AGRI COMMODITY PRICES



Source: Bloomberg

BETTER POGO SPREAD COULD SEE NON-MANDATORY BIODIESEL BLENDING




Source: Bloomberg

PALM OIL PRICE PREMIUM TO SBO IN CHINA NARROWED SIGNIFICANTLY (RMB/TONNE)



Source: Bloomberg

BETTER IMPORT MARGIN IN INDIA



Source: Bloomberg

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2022, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W